Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 5/20 | 0.32 |
| ▸ | CYP2C8 | P10632 | 3/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | IDH1 | O75874 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | FLT3 | P36888 | 1/20 | 0.31 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL909084 | 1.00 | PDK1 (0.36) | PDK1RORCCYP2C8CYP2C9CYP1A2 | |
| SCHEMBL909762 | 1.00 | PDK1 (0.36) | PDK1RORCCYP2C8CYP2C9CYP1A2 | |
| SCHEMBL1107075 | 0.87 | PDK1 (0.40) | PDK1CYP1A2CDK2FLT3CCNA1 | |
| SCHEMBL537576 | 0.87 | PDK1 (0.40) | PDK1CYP1A2CDK2FLT3CCNA1 | |
| SCHEMBL537517 | 0.86 | RORC (0.35) | PDK1RORCCYP2C8CYP2C9CYP2C19 | |
| SCHEMBL1107085 | 0.85 | PDK1 (0.39) | PDK1RORCCYP2C8CYP2C9CYP1A2 | |
| SCHEMBL538258 | 0.85 | PDK1 (0.39) | PDK1RORCCYP2C8CYP2C9CYP1A2 | |
| SCHEMBL1208500 | 0.83 | PDK1 (0.45) | PDK1RORCCDK2FLT3CCNA1 | |
| SCHEMBL3661615 | 0.82 | CYP1A2 (0.37) | PDK1CYP1A2 | |
| SCHEMBL1107086 | 0.82 | CYP1A2 (0.37) | PDK1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2240467-B1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | EVOTEC AG (DE) | 2013-03-20 | — | — | EP | claimed |
| US-20130045973-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | EVOTEC AG | 2013-02-21 | — | — | US | claimed |
| EP-2240467-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | Renovis, Inc. (US) | 2010-10-20 | — | — | EP | claimed |
| EP-2215054-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | Renovis, Inc. (US) | 2010-08-11 | — | — | EP | claimed |
| WO-2009089057-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | RENOVIS, INS. (US) | 2009-07-16 | — | — | WO | claimed |
| WO-2009064449-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | RENOVIS, INC. (US) | 2009-05-22 | — | — | WO | claimed |
| EP-2240467-B1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | EVOTEC AG (DE) | 2013-03-20 | — | — | EP | disclosed |
| EP-2240467-B1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | EVOTEC AG (DE) | 2013-03-20 | — | — | EP | disclosed |
| US-20130045973-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | EVOTEC AG | 2013-02-21 | — | — | US | disclosed |
| US-20130045973-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | EVOTEC AG | 2013-02-21 | — | — | US | disclosed |
| US-20130045973-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | EVOTEC AG | 2013-02-21 | — | — | US | disclosed |
| US-8163901-B2 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | EVOTEC AG (DE) | 2012-04-24 | — | — | US | disclosed |
| US-8163901-B2 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | EVOTEC AG (DE) | 2012-04-24 | — | — | US | disclosed |
| US-20110021514-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | RENOVIS, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| EP-2240467-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | Renovis, Inc. (US) | 2010-10-20 | — | — | EP | disclosed |
| EP-2215054-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | Renovis, Inc. (US) | 2010-08-11 | — | — | EP | disclosed |
| WO-2009089057-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | RENOVIS, INS. (US) | 2009-07-16 | — | — | WO | disclosed |
| WO-2009089057-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | RENOVIS, INS. (US) | 2009-07-16 | — | — | WO | disclosed |
| WO-2009064449-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | RENOVIS, INC. (US) | 2009-05-22 | — | — | WO | disclosed |
| WO-2009064449-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | RENOVIS, INC. (US) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045973-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | TRPV1, TRPA1, TRPV2 | PDK1 1387/4885RORC 2653/4885CYP2C8 1910/4885 |
| US-20110021514-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | TRPV1, TRPA1, TRPV2 | PDK1 1387/4885RORC 2653/4885CYP2C8 1910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.